RIMAB

IMEXHS has lifted first-half underlying EBITDA more than fourfold while building A$4.4 million of contracted annual recurring revenue that had not yet begun billing at June 30. The next test is conversion, particularly as its Aquila+ agentic AI platform moves into production and Colombian healthcare collections remain a working-capital constraint.